BioNTech SE (STU:22UA) EPS (Basic): €-5.07 (TTM As of Mar. 2026)


STU:22UA BioNTech SE STU:22UA
62 GF Score
Price €79.50
GF Value €78.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE EPS (Basic)?

BioNTech SE STU:22UA +0.70% 62 EPS (Basic) is €-5.07 as of Mar. 2026. GuruFocus rates STU:22UA with a GF Score™ of 62/100 and a GF Value™ of €78.33 (Fairly Valued). The stock has 5 warning signs investors should review.

BioNTech SE's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-2.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.07.

BioNTech SE's EPS (Diluted) for the three months ended in Mar. 2026 was €-2.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.07.

BioNTech SE's EPS without NRI for the three months ended in Mar. 2026 was €-1.95. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, BioNTech SE's highest 3-Year average EPS without NRI Growth Rate was 121.60% per year. The lowest was 121.60% per year. And the median was 121.60% per year.

BioNTech SE  (STU:22UA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioNTech SE EPS (Basic) Related Terms

BioNTech SE EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BioNTech SE's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE EPS (Basic) Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.18 38.78 3.87 -2.77 -4.70

BioNTech SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 -1.60 -0.12 -1.25 -2.10
STU:22UA
62GF Score
BioNTech SE STU:22UA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNTech SE EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BioNTech SE's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1136.1-0)/241.700
=-4.70

BioNTech SE's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-531.9-0)/253.286
=-2.10

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-5.07 mean?
BioNTech SE (STU:22UA) has a EPS (Basic) of €-5.07 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's EPS (Basic) too high?
BioNTech SE's current EPS (Basic) is €-5.07. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's EPS (Basic) compare to RPRX and INSM?
BioNTech SE's EPS (Basic) of €-5.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioNTech SE and its competitors. BioNTech SE's current EPS (Basic) is €-5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (STU:22UA) is currently considered Fairly Valued. The stock's GF Value™ is €78.33, compared to a current price of €79.50 — trading 1.5% above its estimated fair value. The current EPS (Basic) is €-5.07. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BioNTech SE (STU:22UA), the current EPS (Basic) is €-5.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (STU:22UA) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of €79.50 is trading 1.5% above its estimated GF Value™ of €78.33. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for STU:22UA:

  • EPS (Basic): €-5.07
  • GF Value™: €78.33 vs. price of €79.50 (1.5% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the STU:22UA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score

Get the complete analysis for STU:22UA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€79.50
Price
€78.33
GF Value